MDX-210 bispecific antibody data

MEDX presented interim results from ongoing Phase I/II trials in late stage, progressive breast cancer patients who have failed multiple prior treatments. Patients are being treated in the U.S., Germany and the Netherlands. Data were presented at the American Society of Clinical Oncology meeting in Philadelphia.

In the U.S. group, patients received multiple doses of MDX-210 in conjunction with granulocyte-colony stimulating factor (G-CSF). To date, 12 patients have received an initial six-week course of therapy at low doses of 1-3.5 mg/m 2. Three patients went on to a second course of treatment based on stabilization or regression of their disease. ...